Polynitro Patents (Class 514/742)
  • Patent number: 10471006
    Abstract: Disclosed is a dry powder oral formulation that includes an active pharmaceutical ingredient (API), a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation. Also disclosed are an excipient composition in absence of an API and methods of making and using the formulations and compositions. Also disclosed is a chewable, swallowable, and/or orally disintegrating tablet comprising an active pharmaceutical ingredient (API), a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: November 12, 2019
    Assignee: MARENDA PHARMACEUTICALS LLC
    Inventors: Andrew Favara, Marc Karetny
  • Patent number: 9278097
    Abstract: The invention provides a medication for the prophylaxis and/or therapy against diseases or complications in connection with portal hypertension, particularly against bleeding complications.
    Type: Grant
    Filed: June 3, 2004
    Date of Patent: March 8, 2016
    Assignee: Universitatsklinikum Freiburg
    Inventors: Wolfgang Kreisel, Peter Deibert
  • Patent number: 8987292
    Abstract: The present invention relates to compositions and methods for treating rectal disorders.
    Type: Grant
    Filed: March 6, 2007
    Date of Patent: March 24, 2015
    Assignee: Salix Pharmaceuticals, Ltd.
    Inventors: Alan Safdi, David Taylor
  • Publication number: 20140377378
    Abstract: Disclosed are methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation. The methods include, for example, obtaining a cylinder containing nitric oxide gas and supplying the cylinder to a medical provider along with instructions regarding how to administer the gas safely to pediatric patients, the instructions including information that patients who have pre-existing left ventricular dysfunction and are administered inhaled nitric oxide may experience pulmonary edema.
    Type: Application
    Filed: September 10, 2014
    Publication date: December 25, 2014
    Applicant: INO THERAPEUTICS LLC
    Inventor: James S. Baldassarre
  • Publication number: 20140187481
    Abstract: A pharmaceutically delivery system is described comprising a pharmaceutically active agent and acidified nitrite as an agent to produce local production of nitric oxide at the skin surface. The dosage form may be in any pharmaceutically acceptable carrier means and comprises an acidifying agent adapted to reduce the pH at the environment. In one embodiment, a barrier consisting of a membrane allows diffusions of the anaesthetic and nitrite ions while preventing direct contact of the skin and acidifying agent.
    Type: Application
    Filed: July 3, 2013
    Publication date: July 3, 2014
    Inventors: Arthur Tudor Tucker, Nigel Benjamin
  • Publication number: 20140170068
    Abstract: In various embodiments methods are provided for identifying a mammal having an elevated risk for an adverse cardiac event (e.g. an MI) and/or determining the prognosis for the mammal. In certain embodiments the methods comprise determining, or causing to be determined, the presence and/or level of antibodies that bind a malondialdehyde-acetaldehyde adduct (MAA adduct) in a biological sample from the mammal, where an elevated level of anti-MAA adduct antibodies, as compared to the level found in a normal healthy mammal is an indicator that that said mammal has one or more atherosclerotic lesions and/or is at elevated risk for a myocardial infarction.
    Type: Application
    Filed: March 12, 2012
    Publication date: June 19, 2014
    Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
    Inventors: Geoffrey M. Thiele, Daniel R. Anderson, Michael J. Duryee
  • Publication number: 20140057977
    Abstract: The present invention inter alia relates to a method of promoting collateral circulation comprising the step of exposing a subject to a therapeutically effective amount of an NO donor wherein the therapeutically effective amount of the NO donor promotes arteriogenesis sufficient to augment collateral circulation in a physiological or pathological condition.
    Type: Application
    Filed: May 29, 2013
    Publication date: February 27, 2014
    Inventor: Michaela Gorath
  • Publication number: 20130331461
    Abstract: Solid pharmaceutical preparation with the active substance glyceryl trinitrate for oromucosal or oral administration characterized in that it contains between 0.05 and 2 weight % glyceryl trinitrate, at least one carrier material, and at least one substance that reduces the volatility of the GTN, whereby this substance is a non-volatile ester stabilizer.
    Type: Application
    Filed: February 24, 2012
    Publication date: December 12, 2013
    Applicant: G. Pohl-Boskamp GmbH & Co. KG
    Inventors: Thomas Zimmeck, Henning Ueck, Julia Zscherpe
  • Patent number: 8569384
    Abstract: Antimicrobial compositions are provided that include a hydroalcoholic solvent system comprising a lower C2-C5 alcohol and water; a cationic antimicrobial agent such as chlorhexidine gluconate; a fatty component containing at least one free hydroxyl group, such as a C12-C21 fatty alcohol, a C12-C21 fatty ester, a C12-C21 fatty ether, a C12-C21 fatty amide, and combinations thereof; and optionally an emollient ester such as diesters of bibasic acids and trimesters of citric acid. The compositions described herein display improved antimicrobial efficacy and improved cosmetic elegance. Methods of using the antimicrobial compositions are provided.
    Type: Grant
    Filed: November 13, 2012
    Date of Patent: October 29, 2013
    Assignee: 3M Innovative Properties Company
    Inventors: Robert A. Asmus, Terry R. Hobbs
  • Publication number: 20130189333
    Abstract: An oral product includes a body that is wholly receivable in an oral cavity. The body includes a mouth-stable polymer matrix, cellulosic fibers embedded in the mouth-stable polymer matrix, and an additive dispersed in the mouth-stable polymer matrix. The oral product is adapted to release the additive from the body when the body is received within the oral cavity and exposed to saliva.
    Type: Application
    Filed: January 18, 2013
    Publication date: July 25, 2013
    Applicant: ALTRIA CLIENT SERVICES INC.
    Inventor: Altria Client Services Inc.
  • Publication number: 20130123354
    Abstract: Disclosed herein are novel compositions and methods for treating or preventing a variety of disorders and conditions associated with lipid metabolism. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more sGC modulators alone or in combination with one or more lipid altering agents and/or PDE inhibitors.
    Type: Application
    Filed: January 8, 2013
    Publication date: May 16, 2013
    Applicant: Ironwood Pharmaceuticals, Inc.
    Inventor: Ironwood Pharmaceuticals, Inc.
  • Publication number: 20130079311
    Abstract: The invention provides compositions and methods for the convenient compounding of pharmaceuticals. Single and multiple unit of use kits are provided which contain all the necessary components required for preparing a compounded pharmaceutical. The kits of the invention include a first container having a first active agent and a second container having at least one second inactive agent. The kits of the invention are also useful for compounding veterinary pharmaceuticals.
    Type: Application
    Filed: September 27, 2012
    Publication date: March 28, 2013
    Applicant: CutisPharma, Inc.
    Inventor: Indu Muni
  • Patent number: 8377925
    Abstract: The present invention provides compounds of Formula (I) that are useful for modulating the biological activity of the melanocortin-5 receptor (MC5R). Compounds of this invention can be used to treat diseases and/or conditions in which downregulation of MC5R is beneficial. Such diseases and/or conditions include, but are not limited to, acne, seborrhea, seborrheic dermatitis, cancer, and inflammatory diseases.
    Type: Grant
    Filed: February 24, 2009
    Date of Patent: February 19, 2013
    Assignee: Mimetica Pty Ltd
    Inventors: Mark Arnold Thomas Blaskovich, Peter Joseph Cassidy
  • Patent number: 8338491
    Abstract: Antimicrobial compositions are provided that include a hydroalcoholic solvent system comprising a lower C2-C5 alcohol and water; a cationic antimicrobial agent such as chlorhexidine gluconate; a fatty component containing at least one free hydroxyl group, such as a C12-C21 fatty alcohol, a C12-C21 fatty ester, a C12-C21 fatty ether, a C12-C21 fatty amide, and combinations thereof; and optionally an emollient ester such as diesters of bibasic acids and triesters of citric acid. The compositions described herein display improved antimicrobial efficacy and improved cosmetic elegance.
    Type: Grant
    Filed: October 25, 2007
    Date of Patent: December 25, 2012
    Assignee: 3M Innovative Properties Company
    Inventors: Robert A. Asmus, Terry R. Hobbs
  • Patent number: 8318721
    Abstract: A method and composition are provided for the treatment of an anorectal disorder and for controlling the pain associated therewith. The method comprises administering to a subject in need of such treatment therapeutically effective amounts of a calcium channel blocker either alone or together with a nitric oxide donor. Amlodipine, anipamil, barnidipine, benidipine, bepridil, darodipine, diltiazem, efonidipine, felodipine, isradipine, lacidipine, lercanidipine, lidoflazine, manidipine, mepirodipine, nicardipine, nifedipine, niludipine, nilvadipine, nimodipine, nisoldipine, nitrendipine, perhexiline, tiapamil, verapamil and pharmaceutically acceptable salts thereof, are suitable calcium channel blockers.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: November 27, 2012
    Assignee: S.L.A. Pharma AG
    Inventors: Michael A. Kamm, Robin K. S. Phillips
  • Publication number: 20120237615
    Abstract: The present invention provides O-nitro compounds, pharmaceutical compositions of O-nitro compounds and methods of using O-nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Application
    Filed: May 30, 2012
    Publication date: September 20, 2012
    Applicants: RADIORX, INC., C/O INTERWEST VENTURE PARTNERS, ALLIANT TECHSYSTEMS INC.
    Inventors: Mark D. Bednarski, Lynn M. Oehler, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Publication number: 20120220578
    Abstract: Described are pharmacological compositions comprising a gum resin; a pharmacologically active agent and a topically acceptable volatile solvent for the gum resin and active agent. Also described are methods for the transdermal or transmucosal delivery of a pharmacologically active agent using such compositions.
    Type: Application
    Filed: May 4, 2012
    Publication date: August 30, 2012
    Inventors: Alex Battaglia, Eva Beim
  • Publication number: 20120149678
    Abstract: The invention provides organonitro compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat non-Hodgkin's lymphoma and certain leukemias in a patient. The compounds, compositions, kits, and methods are contemplated to provide a therapeutic benefit in treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, and acute lymphoblastic leukemia. Exemplary organonitro compounds described herein include alkyl-substituted and acyl-substituted di-nitroheterocycles.
    Type: Application
    Filed: December 9, 2011
    Publication date: June 14, 2012
    Inventors: Bryan T. Oronsky, Susan Knox, Jan Scicinski, Shoucheng Ning
  • Patent number: 8106099
    Abstract: The invention relates to the combination of one or more IKr channel blockers and of one or more Kv1.5 blockers, in particular phenyl-carboxamides of the formula Ia or Ib or pharmaceutically tolerable salts thereof, and the use of the combination for the treatment of atrial arrhythmias.
    Type: Grant
    Filed: March 9, 2004
    Date of Patent: January 31, 2012
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Joachim Brendel, Klaus Wirth, Heinz Goegelein, Maurits Allessie, Yuri Blaauw
  • Publication number: 20110300232
    Abstract: Nitric Oxide (NO) acts as double-edged sword, which induces and prevents cell death, depending on various factors. The mechanism for the NO regulation of cells is not fully understood. The present invention provides experiment design methods and therapy design methods leveraging viable hypothesis supported by current research findings. This invention determines the effects of NO by controlling the majority parameters such as the steady-state concentration of NO, duration of NO exposure and the local level of oxygen. The experiment designs are structured to improve understanding of NO regulation of cells, and further can be directly adapted for therapy design. The invention directs these experiment design and therapy design methods to the study and treatment of cancer. In an application, the effects of exogenous NO on inducible Nitric Oxide Synthase (iNOS) expression and signal transduction in ovarian cancer is applied to drug discovery and therapy design for ovarian and other cancers.
    Type: Application
    Filed: June 7, 2011
    Publication date: December 8, 2011
    Inventor: Pooncharas Tipgunlakant
  • Patent number: 8067464
    Abstract: The invention describes novel compositions comprising at least one apocynin compound or a pharmaceutically acceptable salt thereof, and at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The invention also provides novel kits comprising at least one apocynin compound or a pharmaceutically acceptable salt thereof, and at least one nitric oxide donor compound, and, optionally, at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating gastrointestinal disorders; (h) treating inflammatory disorders; and (j) treating respiratory disorders; and (k) treating peripheral vascular diseases. The apocynin compound may preferably be apocynin.
    Type: Grant
    Filed: October 3, 2005
    Date of Patent: November 29, 2011
    Assignee: Nitromed, Inc.
    Inventor: David S. Garvey
  • Patent number: 8048875
    Abstract: Bethanechol, diltiazem, or a combination thereof is administered locally to the anus for the treatment of benign anal disorders, in particular anal fissures and hemorrhoids. The agents induce a reduction in the mean and resting pressure, thereby assisting in the healing of the anal fissures and hemorrhoids.
    Type: Grant
    Filed: February 23, 1997
    Date of Patent: November 1, 2011
    Assignee: S.L.A. Pharma AG
    Inventors: Michael A. Kamm, Robin K. S. Phillips
  • Patent number: 7910574
    Abstract: A method for controlling schistosome parasites in a mammal comprising delivering an effective amount of an agent for silencing TGR activity in the parasites.
    Type: Grant
    Filed: December 11, 2007
    Date of Patent: March 22, 2011
    Assignee: Illinois State University
    Inventors: David L. Williams, Ahmed Sayed
  • Publication number: 20100330193
    Abstract: The invention relates methods of reducing the risk or preventing the occurrence of an adverse event (AE) or a serious adverse event (SAE) associated with a medical treatment comprising inhalation of nitric oxide.
    Type: Application
    Filed: June 22, 2010
    Publication date: December 30, 2010
    Applicant: Ikaria Holdings, Inc.
    Inventors: James S. Baldassarre, Ralf Rosskamp
  • Publication number: 20100234828
    Abstract: Provided are methods and compositions for locally increasing arterial diameter and providing local anesthesia in a subject. The methods include applying to a skin site of the subject a topical composition that includes a vasodilation agent and an anesthetic agent in a manner sufficient for locally increasing arterial diameter and providing local anesthesia in the subject. In some embodiments, the method includes inserting a cannula into an artery at the skin site of the subject. Also provided are topical compositions that find use in performing the subject methods.
    Type: Application
    Filed: February 25, 2010
    Publication date: September 16, 2010
    Inventors: Andrew Boyle, David Majure
  • Publication number: 20100216893
    Abstract: A pharmaceutical preparation containing the active substance glyceryl trinitrate having improved storage stability in a container. The improved storage stability is achieved by the addition of a proton-absorbing substance either as part of the preparation as placed into the container or applied to the surface of the preparation's storage container before the remaining components of the preparation are placed into the container. The preparation can preferably be filled into a plastic bottle having a spray pump.
    Type: Application
    Filed: March 31, 2010
    Publication date: August 26, 2010
    Applicant: G. POHL-BOSKAMP GMBH & CO. KG
    Inventors: Rolf Groteluschen, Henning Ueck, Thomas Zimmeck
  • Publication number: 20100215756
    Abstract: The subject of the present invention is a transdermal preparation containing pharmaceutically active ingredient, wherein the particles of the active ingredient are coated with highly volatile silicones or a mixture thereof, and these coated particles are dispersed in a gel or cream base. The volatile silicone component is hexamethyldisiloxane and/or octamethyltrisiloxane and/or decamethylpentacyclo-siloxane. A further subject of the present invention is a method for the preparation of such pharmaceutical compositions.
    Type: Application
    Filed: July 10, 2008
    Publication date: August 26, 2010
    Inventors: Endre Mikulásik, Patrik Fazekas
  • Publication number: 20100210565
    Abstract: Apparatus and methods deliver physiologically active agents in the presence of adjuvant gases. The adjuvant gases can enhance the effectiveness of the drug, lower the dosage of drug or concentration of drug necessary to achieve a therapeutic result, or both. Exemplary adjuvant gases include carbon dioxide, nitric oxide, nitrous oxide, and dilute acid gases.
    Type: Application
    Filed: April 28, 2010
    Publication date: August 19, 2010
    Inventors: Julia S. Rasor, Ned S. Rasor, Gerard Pereira
  • Publication number: 20100184870
    Abstract: A pharmaceutical preparation containing the active substance glyceryl trinitrate having improved storage stability in a container. The improved storage stability is achieved by the addition of a proton-absorbing substance either as part of the preparation as placed into the container or applied to the surface of the preparation's storage container before the remaining components of the preparation are placed into the container. The preparation can preferably be filled into a plastic bottle having a spray pump.
    Type: Application
    Filed: March 16, 2009
    Publication date: July 22, 2010
    Inventors: ROLF GROTELUSCHEN, Henning Ueck, Thomas Zimmeck
  • Publication number: 20100152120
    Abstract: Apparatus and methods deliver physiologically active agents in the presence of adjuvant gases. The adjuvant gases can enhance the effectiveness of the drug, lower the dosage of drug or concentration of drug necessary to achieve a therapeutic result, or both. Exemplary adjuvant gases include carbon dioxide, nitric oxide, nitrous oxide, and dilute acid gases.
    Type: Application
    Filed: February 18, 2010
    Publication date: June 17, 2010
    Inventors: Julia S. Rasor, Ned S. Rasor, Gerard F. Pereira
  • Publication number: 20100144864
    Abstract: Disclosed herein are novel compositions and methods for treating or preventing a variety of disorders and conditions associated with lipid metabolism. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more sGC modulators alone or in combination with one or more lipid altering agents and/or PDE inhibitors.
    Type: Application
    Filed: April 3, 2008
    Publication date: June 10, 2010
    Applicant: IRONWOOD PHARMACEUTICALS, INC.
    Inventors: Mark G. Currie, Daniel P. Zimmer
  • Publication number: 20100068301
    Abstract: Disclosed herein are compositions and compounds that combine an inhibitor of 5-lipoxygenase activating protein (FLAP) and a modulator of NO levels in a mammal. The NO modulator can be an agent that induces the production of NO in a mammal, or can be an agent that itself produces NO in the mammal. Further disclosed herein are strategies for synthesizing such compounds, and methods for testing whether the combination compounds and compositions provide a desired benefit. Also disclosed herein are pharmaceutical compositions and formulations that combine a FLAP inhibitor and an NO modulator. Further described herein are methods for using such compositions and compounds for the treatment of diseases, conditions, and disorders in a mammal, including a human. Such treatment methods include the separate administration of a FLAP inhibitor and a NO modulator to the mammal, and the simultaneous administration of a FLAP inhibitor and a NO modulator to the mammal.
    Type: Application
    Filed: November 30, 2007
    Publication date: March 18, 2010
    Inventors: John H. Hutchinson, Mustapha Haddach, Mark Moran, Jillian Evans, Nicholas Simon Stock, Jeffrey Roger Roppe
  • Publication number: 20100034902
    Abstract: The present invention provides methods for measuring, detecting, diagnosing, treating, and researching salt sensitivity and related conditions. In particular, the present invention provides methods for measuring, detecting, diagnosing, treating, and researching salt sensitivity through measuring aberrant red blood cell based potassium efflux levels. In addition, the present invention provides methods for treating conditions involving salt sensitivity (e.g., hypertension), preventing the onset of conditions involving salt sensitivity, identifying individuals at risk for developing salt sensitivity and related conditions, identifying new types of treatment for salt sensitivity and related conditions, and evaluating the effectiveness of treatments for conditions involving salt sensitivity (e.g., hypertension).
    Type: Application
    Filed: January 17, 2008
    Publication date: February 11, 2010
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Maria Carolina Delgado, Bertram Pitt
  • Publication number: 20100016446
    Abstract: Disclosed are stable, water-based topical creams comprising nitroglycerin and suitable for pharmaceutical and/or cosmetic use. Also disclosed are methods for preparing the creams. Also disclosed are methods for treating circulatory disorders, methods for preventing or alleviating insufficient circulation, methods for enhancing localized activity of systemically administered drugs, methods for enhancing circulation, and methods for promoting wound healing by administering the disclosed creams. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: July 21, 2009
    Publication date: January 21, 2010
    Inventors: Sylvia Gonda, Matthew A. Gonda
  • Publication number: 20090304815
    Abstract: The invention relates to a method of treatment for muscular dystrophies, including Duchenne, Becker, limb-girdle, facioscapulohumeral, congenital muscular dystrophies and the like using a combination of nitric oxide-releasing and anti-inflammatory compounds.
    Type: Application
    Filed: February 1, 2007
    Publication date: December 10, 2009
    Inventors: Giulio Cossu, Emilio Clementi, Silvia Brunelli
  • Publication number: 20090088367
    Abstract: This invention relates to Applicant's discovery that Metabolic Syndrome, a cluster of disorders stemming from a resistance to insulin, contributes directly to dementia, particularly Alzheimer's disease. Applicant's invention includes a screening method to determine susceptibility and diagnosis of dementia based on the risk factors for Metabolic Syndrome. Applicant's invention further includes methods for the prevention or treatment of dementia and other neurological conditions based on (1) minimizing insulin resistance, thereby preventing excess biosynthesis of insulin; (2) modulating the activity of IDE such that insulin competes less efficiently with ?-amyloid protein for the IDE; and (3) blocking the consequences of NMDA receptor activation, such as by minimizing the generation of NO and other harmful free radicals.
    Type: Application
    Filed: May 10, 2005
    Publication date: April 2, 2009
    Applicant: Burnham Institute For Medical Research
    Inventors: Stuart A. Lipton, Daniel Einhorn
  • Patent number: 7498361
    Abstract: The present invention describes a novel treatment for movement disorders, including tardive dyskinesia, tic disorders, Tourette's syndrome, and blepharospasm, and other focal dystonias. The treatment of the present invention utilizes agents that simultaneously act as NMDA-type glutamate receptor antagonists and GABA-A receptor agonists. Preferably these two activities are characteristic of a single agent, for example acamprosate. Alternatively, separate agents having these activities can be combined and administered together. The invention also provides a third agent that acts as a non-competitive NMDA-receptor blocking agent or ion channel blocker that augments the effect of the primary treatment. A particularly preferred ion channel blocking agent is magnesium. Alternatively, magnesium can be administered alone for prevention and treatment of movement disorders.
    Type: Grant
    Filed: June 27, 2001
    Date of Patent: March 3, 2009
    Assignee: Synchroneuron, LLC
    Inventor: Barry S. Fogel
  • Publication number: 20090018214
    Abstract: A composition for topical application to a part of the body comprises a local anaesthetic and optionally a vasodilator as active ingredient dissolved in a blend of volatile and non-volatile solvents of different solvating capacities for the active ingredient. The vasodilator may comprise glyceryl trinitrate and the local anaesthetic may comprises an anaesthetic of the aminoamide or aminoester type. The volatile solvent may comprise a mixture of water with a C1-C5 alcohol and the non-volatile solvent may comprise a polyhydric alcohol and optionally a glycol. A low-concentration vasodilator-containing composition is also described. The compositions allow a “virtual injection” of the active ingredient to be delivered transdermally without general systemic uptake.
    Type: Application
    Filed: January 23, 2007
    Publication date: January 15, 2009
    Inventor: Adrian Francis Davis
  • Publication number: 20080311099
    Abstract: Methods for treating angina are described. A method for treating angina includes concurrently administering a compound with a therapeutic cardiovascular compound. A combination therapy employs suitable therapeutic cardiovascular compounds, such as a calcium channel blocker, a ?-adrenergic blocker, nitrates, partial fatty acid oxidation inhibitors, potassium channel activators, or a mixture thereof, in combination with a compound such as pyridoxal-5?phosphate, pyridoxic acid, pyridoxal, pyridoxamine, 3-acylated analogues of pyridoxal, 3-acylated analogues of pyridoxal-4,5-aminal, pyridoxine phosphonate analogues, a pharmaceutically acceptable acid addition salt thereof, or a mixture thereof. The invention also includes a novel composition comprising at least one compound and nitrates, partial fatty acid oxidation inhibitors, potassium channel activators, calcium channel blockers, ?-adrenergic blockers, or a mixture thereof.
    Type: Application
    Filed: September 26, 2005
    Publication date: December 18, 2008
    Inventor: Albert Friesen
  • Publication number: 20080260861
    Abstract: Methods and compositions for modulating lymphatic function, e.g., by altering NO levels, are disclosed.
    Type: Application
    Filed: April 7, 2005
    Publication date: October 23, 2008
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Jeroeng Hagendoorn, Dai Fukumura, Timothy P. Padera, Rakesh K. Jain
  • Publication number: 20080242722
    Abstract: The invention is directed to a method for treating a cyclooxygenase-2 mediated disease or condition in a mammalian patient at risk of a thrombotic cardiovascular event, wherein the patient is on aspirin therapy to reduce the risk of the thrombotic cardiovascular event, comprising orally concomitantly or sequentially administering to the patient a cyclooxygenase-2 selective inhibitor in an amount effective to treat the cyclooxygenase-2 mediate disease or condition, and a nitric oxide donating compound in accordance with Formula I or a pharmaceutically acceptable salt thereof, wherein the nitric oxide donating compound is administered in an amount effective to reduce the gastrointestinal toxicity caused by the combination of the cyclooxygenase-2 selective inhibitor and aspirin. Pharmaceutical compositions are also encompassed.
    Type: Application
    Filed: January 25, 2005
    Publication date: October 2, 2008
    Inventors: Claude Dufresne, Carl Berthelette, Lianhai Li, Daniel Guay, Michel Gallant, Patrick Lacombe, Renee Aspiotis, Zhaoyin Wang, Claudio Sturino
  • Publication number: 20080220092
    Abstract: Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, Alzheimer's disease, sleep disorders, Parkinson's disease, Attention Deficit Disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances (for example, stimulants) in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible.
    Type: Application
    Filed: October 31, 2007
    Publication date: September 11, 2008
    Applicant: CHRONO THERAPEUTICS, INC.
    Inventors: Guy Dipierro, Steven A. Giannos
  • Publication number: 20080175831
    Abstract: A treatment is disclosed for alleviation or prevention of abnormal blood flow to various organs such as the eye, brain, kidneys, heart, feet and other tissues of organs with fine vascular networks that can lead to neurodegeneration as is seen in wet age-related macular degeneration (AMD), epilepsy and diabetes, in which an effective amount of a blood flow regulatory drug is administered to a subject in need of it. Illustrative blood flow regulatory drugs include anticoagulants and vasodilators, and their mixtures.
    Type: Application
    Filed: December 20, 2007
    Publication date: July 24, 2008
    Inventors: Stephen L. Macknik, Susana Martinez-Conde
  • Patent number: 7399821
    Abstract: The invention relates to a method for removing bile salts from a patient in need thereof and compositions useful in the method. The method comprises administering to the patient a therapeutically effective amount of a salt of an alkylated and crosslinked polymer. The alkylated and crosslinked polymer salt comprises the reaction product of crosslinked polymers, or salts and copolymers thereof having amine containing repeat units, with at least one aliphatic alkylating agent.
    Type: Grant
    Filed: July 24, 2006
    Date of Patent: July 15, 2008
    Assignee: Genzyme Corporation
    Inventors: W. Harry Mandeville, III, Stephen Randall Holmes-Farley
  • Patent number: 7393825
    Abstract: Methods for treating vascular conditions associated with localized imbalance in vascular tone, which are hypothesized to be largely due to elevated endothelin (ET) are provided. The methods involve administration of nitric oxide (NO), agents which are able to provide NO, such as NO donors, agents which activate guanyl cyclase, such as YC-1, or agents which prolong the actions of endogenous NO or cyclic guanosine monophosphate (cGMP; a 2nd messenger molecule), such as phosphodiesterase (PDE) inhibitors. According to the invention, such agents are administered in minimal doses or microdoses by any route known in the art, so as to provide dosages which are about one half to about one twentieth (½ to 1/20) of those known to induce vasodilation in “normal” circulations.
    Type: Grant
    Filed: June 11, 2003
    Date of Patent: July 1, 2008
    Assignee: Strakan International Limited
    Inventors: Jeremy P. W. Heaton, Michael A. Adams, James D. Banting
  • Publication number: 20080025972
    Abstract: Sex steroid potentiated disorders including, prostate cancer and breast cancer, in a patient in need of treatment thereof, are treated with an amount of nitric oxide donating compound and/or nitrosoglutathione reductase inhibitor and/or cysteine binder different from that provided by nitric oxide donating compound effective to inhibit activation of steroid receptor. Variations include using only nitric oxide donating agent as treating agent; using only nitrosoglutathione reductase inhibitors as treating agent, using nitric oxide donating agent plus nitrosoglutathione reductase inhibiting agent; for prostate cancer treatment using prostate cancer drug modified to contain nitric oxide donating moiety or FDA approved nitric oxide donating agent and FDA approved prostate cancer treating agent. Also disclosed is an assay for assessing mutagenic potential of prostate cancer in a patient.
    Type: Application
    Filed: May 21, 2007
    Publication date: January 31, 2008
    Applicant: Duke University
    Inventors: Yehia Daaka, Jonathan S. Stamler
  • Patent number: 7189761
    Abstract: A pharmaceutical composition contains a nitric oxide donor and advantageously an optional corticosteroid and/or topical anesthetic. The composition is useful in a method for treating anal disorders such as anal fissure, anal ulcer, hemorrhoidal disease, levator spasm, and so forth, by topical application to or proximate the affected area.
    Type: Grant
    Filed: September 22, 2003
    Date of Patent: March 13, 2007
    Inventor: Stephen R. Gorfine
  • Patent number: 7157500
    Abstract: Nitrosylation of proteins and amino acid groups enables selective regulation of protein function, and also endows the proteins and amino acids with additional smooth muscle relaxant and platelet inhibitory capabilities. Thus, the invention relates to novel compounds achieved by nitrosylation of protein thiols. Such compounds include: S-nitroso-t-PA, S-nitroso-cathepsin; S-nitroso-lipoprotein; and S-nitroso-immunoglobulin. The invention also relates to therapeutic use of S-nitroso-protein compounds for regulating protein function, cellular metabolism and effecting vasodilation, platelet inhibition, relaxation of non-vascular smooth muscle, and increasing blood oxygen transport by hemoglobin and myoglobin. The compounds are also used to deliver nitric oxide in its most bioactive form in order to achieve the effects described above, or for in vitro nitrosylation of molecules present in the body.
    Type: Grant
    Filed: August 13, 2002
    Date of Patent: January 2, 2007
    Assignee: Brigham and Women's Hospital
    Inventors: Jonathan Stamler, Joseph Loscalzo, Daniel Simon, David Singel
  • Patent number: 7148259
    Abstract: Hydroxyamidines and related compounds are provided which are suitable as antibacterial agents.
    Type: Grant
    Filed: February 1, 2006
    Date of Patent: December 12, 2006
    Assignee: Amgen Inc.
    Inventors: Leping Li, Xiaoqi Chen, Pingchen Fan, Jeffrey Thomas Mihalic, Serena Cutler
  • Patent number: 6903100
    Abstract: The present invention is directed to the treatment of multiple sclerosis by periodically administering a high dose of methotrexate at a level sufficiently high to cross the blood brain barrier. The methotrexate administration is accompanied by leucovorin rescue of the periphery. The high dose methotrexate is preferably administered at 1 to 4 month intervals. The periodic high dose methotrexate treatment may be used in conjunction with interim treatments using a therapeutic agent that is effective in treating MS, but does not cross the BBB in cytotoxic amounts. It is contemplated that the method of the present invention may be employed to treat other non-infectious, non-neoplastic inflammatory conditions of the CNS.
    Type: Grant
    Filed: April 24, 2002
    Date of Patent: June 7, 2005
    Assignee: MidAmerica Neuroscience Research Foundation
    Inventor: Vernon D. Rowe